Shares of Chinese and South Korean med-tech companies continued to rise after the World Health Organization declared mpox a public health emergency of international concern Aug. 14 after recent outbreaks.
The Institute of Physical and Chemical Research, the National Institute of Infectious Diseases Japan and Shizuoka Prefectural University have discovered prodrugs of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors and reported to be useful for the treatment of viral infection.
Researchers from Thomas Jefferson University and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) have published findings from preclinical studies of LASSARAB, a new rabies-based Lassa virus (LASV) vaccine candidate.
About two months after Astrazeneca plc said its application for sipavibart (AZD-3152) had been accepted by the EMA for pre-exposure prophylaxis (PrEP) against COVID-19 in immunocompromised people, Invivyd Inc. unveiled positive 180-day exploratory efficacy data from the company’s ongoing Canopy phase III trial with Pemgarda (pemivibart) in the same indication – and made known less happy news from regulators on the other side of the pond.
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
Immorna Biotherapeutics Inc. has received a grant from the Bill & Melinda Gates Foundation to support the clinical development of JCXH-108, a monovalent respiratory syncytial virus (RSV) vaccine based on Immorna’s proprietary mRNA and ready-to-use (RTU)-lipid nanoparticle (LNP) technologies.
The inappropriate use of antibiotics over long periods of time has led to increasing bacterial drug resistance. Quinolones are among the most effective and widely used antibacterials, and there are ongoing efforts to develop new quinolone-based drugs able to overcome emerging bacterial drug resistance.
HIV-1 infects lymphocytes and macrophages, gradually destroying the immune system. Multiple treatment combinations suppress the viral load to undetectable levels, but their long-term use leads to adverse effects. Allosteric inhibition of HIV-1 integrase has emerged as a source for new treatment strategies.
The BioWorld Infectious Disease Index (BIDI) has rebounded significantly from its lowest point this year, improving from a 25.12% drop in late April to a 7.66% decline by the end of July. Despite the recovery, BIDI still lagged behind the Nasdaq Biotechnology Index, which rose 10.82% by July’s close, and the Dow Jones Industrial Average, which gained 8.25% year to date.
Quantamatrix Inc. is advancing an Ultra-Rapid Antimicrobial Susceptibility Testing sepsis diagnostic test, touted as having the world’s fastest all-in-one antimicrobial technology, to reduce sepsis diagnosis time from days to an average of 13 hours.
RSS
